Registry following people newly evaluated for light chain amyloidosis across Europe
Collects information and samples from adults with AL amyloidosis to study the disease.
Plain-language title generated from the registry record
Registry title: A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)
Key facts
- Where
- Pavia, ItalySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT06205953, who can take part
Where in Italy
- Fondazione IRCCS Policlinico San Matteo, Pavia, Viale Golgi 19, 27100Pavia, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Trial code
- NCT06205953
- Record updated
- 16 April 2026
- Original description
A prospective patients' registry collecting all new cases of AL amyloidosis evaluated at referral Centers from across Europe and a sample sharing network will be created to study mechanisms of the disease through the use of advanced molecular technologies and big data analysis tools.Read full original descriptionShow less
Bonding Molecular Genotyping and Phenotyping to Outcome Measures in AL Amyloidosis: A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)
A prospective patients' registry collecting all new cases of AL amyloidosis evaluated at referral Centers from across Europe and a sample sharing network will be created to study mechanisms of the disease through the use of advanced molecular technologies and big data analysis tools.
Inclusion: diagnosis of systemic AL amyloidosis; treatment-naïve; age ≥18 years; ability to understand and willingness to sign an informed consent; planned follow-up at participating center.
Exclusion: previous treatment for AL amyloidosis; non-AL amyloidosis.